|
Vol 57(2023) N 2 p. 291-298; DOI 10.1134/S0026893323020152  L.A. Oleinik1*, P.G. Madonov1, M.B. Pykhtina1 Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2 1Research Institute of Clinical and Experimental Lymphology-Branch of Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090 Russia*larisaoleynik81@gmail.com Received - 2022-08-05; Revised - 2022-10-06; Accepted - 2022-10-06 This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020-2022. The results of our own studies of pharmacological substances based on recombinant IFN-λ1 and its pegylated form are also presented. Completed and ongoing investigations allow us to position IFN-λ as an effective therapeutic agent against SARS-CoV-2. SARS-CoV-2, recombinant human interferon-λ1, PEG-interferon-λ1, antiviral activity |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
